Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 7/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLR1A | O95602 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403708 | 0.94 | KDM4E (0.48) | KDM4EMAPTHTR2CMCHR1THRB | |
| SCHEMBL3401208 | 0.93 | HTR2C (0.44) | KDM4EMAPTHTR2CTHRBPOLR1A | |
| SCHEMBL3402535 | 0.89 | HTR2C (0.52) | MAPTHTR2CMCHR1POLR1ACNR1 | |
| SCHEMBL3404372 | 0.88 | HTR2C (0.41) | HTR2CTHRBPOLR1A | |
| SCHEMBL3402247 | 0.87 | HTR2C (0.47) | KDM4EMAPTHTR2CTHRBCNR1 | |
| SCHEMBL3405078 | 0.87 | HTR2C (0.47) | KDM4EMAPTHTR2CMCHR1THRB | |
| SCHEMBL3398510 | 0.85 | HTR2C (0.50) | MAPTHTR2CPOLR1APPARAPPARD | |
| SCHEMBL3401299 | 0.84 | ACKR3 (0.47) | HTR2CPOLR1A | |
| SCHEMBL3405373 | 0.84 | THRA (0.44) | KDM4EHTR2CTHRBPOLR1ACNR1 | |
| SCHEMBL3401811 | 0.84 | HTR2C (0.45) | HTR2CTHRBPOLR1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | KDM4E 3449/4885MAPT 342/4885HTR2C 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.